CLPT ClearPoint Neuro, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1285550 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY32.5%
TTM net income YoY-56.2%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—
Margins
Gross margin61.4%
Operating margin-70.6%
Net margin-79.4%
FCF margin-106.0%
EBITDA margin-69.3%
Returns
ROE-167.5%
ROA-41.8%
ROIC (approx.)-130.8%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets75.8%
Debt / equity1.86x
Current ratio6.76x
Interest coverage-6.03x
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio12.7%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $36.97M | $31.39M |
| Cost of revenue | $14.28M | $12.27M |
| Gross profit | $22.69M | $19.12M |
| R&D expense | $13.90M | $12.39M |
| SG&A expense | $16.50M | $11.99M |
| Operating income | -$24.16M | -$19.73M |
| Interest expense | $2.39M | $518,000 |
| Pretax income | -$25.48M | -$18.90M |
| Income tax | $55,000 | $12,000 |
| Net income | -$25.54M | -$18.91M |
| EBITDA | -$23.35M | -$18.75M |
| EPS (basic) | -0.90 | -0.70 |
| EPS (diluted) | -0.90 | -0.70 |
| Weighted avg. shares (diluted) | 28.32M | 27.03M |
| Banking | ||
| Net interest income | — | $872,000 |
| Balance sheet | ||
| Cash & equivalents | $45.92M | $20.10M |
| Receivables | $6.55M | $4.71M |
| Inventory | $8.36M | $6.86M |
| Current assets | $63.60M | $33.36M |
| PP&E, net | $2.62M | $2.00M |
| Goodwill | $7.47M | $7.47M |
| Intangibles | $13.92M | $0 |
| Total assets | $97.75M | $39.19M |
| Current liabilities | $10.77M | $10.35M |
| Long-term debt | $49.08M | — |
| Total debt | $49.08M | — |
| Total liabilities | $69.73M | $13.80M |
| Shareholders' equity | $28.02M | $25.39M |
| Net debt | $3.15M | — |
| Shares outstanding | 29.37M | 27.62M |
| Cash flow statement | ||
| Operating cash flow | -$23.93M | -$8.95M |
| Capital expenditure | $522,000 | $275,000 |
| Free cash flow | -$24.45M | -$9.22M |
| Investing cash flow | $615,000 | -$275,000 |
| Financing cash flow | $50.18M | $6.19M |
| Depreciation & amortization | $814,000 | $980,000 |
| Stock-based compensation | $8.18M | $6.91M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.